ArticleNeuropsychiatric disease and treatment2011
Pharmacotherapy for treatment-resistant schizophrenia.
Article in Neuropsychiatric disease and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Treatment of clozapine-associated weight gain: a systematic review.European journal of clinical pharmacology · 2015Pooled it
- Exploring comorbidity patterns of psychosis-related post-traumatic stress disorder and depression symptoms in stabilised hospitalised schizophrenia patients and relationships with sleep quality and quality of life: a latent profile analysis.European journal of psychotraumatology · 2026Article
- Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016.Journal of neural transmission (Vienna, Austria : 1996) · 2024Observational
- Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives.Frontiers in psychiatry · 2022Review
- Towards in vivo imaging of functionally active 5-HTTranslational psychiatry · 2021Review
- Clinical Effectiveness of Maintenance Electroconvulsive Therapy in Patients with Schizophrenia: A Retrospective Cohort Study.The journal of ECT · 2020Article
- The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling.Drug design, development and therapy · 2020Article
- Clozapine augmentation strategies.The mental health clinician · 2019Article
- Identifying and characterizing treatment-resistant schizophrenia in observational database studies.International journal of methods in psychiatric research · 2019Article
- Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study.The international journal of neuropsychopharmacology · 2019Article
- Acute onset clozapine-induced hyperglycaemia: A case report.General psychiatry · 2019Article
- Validation of gallbladder absorbed radiation dose reduction simulation: human dosimetry of [EJNMMI physics · 2018Article
- Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?Schizophrenia research · 2018Article
- Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial.BJPsych open · 2015Article
- Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar.Metabolic brain disease · 2015Article
- Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia.The international journal of neuropsychopharmacology · 2015Article
- Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.Psychopharmacology · 2014Article
- Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.Clinical drug investigation · 2014Article
- Sialorrhea and aspiration pneumonia: a case study.Innovations in clinical neuroscience · 2013Article
- Clozapine prescribing in a Canadian outpatient population.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.